Please login to the form below

Not currently logged in
Email:
Password:

Merck

This page shows the latest Merck news and features for those working in and with pharma, biotech and healthcare.

Pharma fears “lack of focus” on no-deal Brexit preparations

Pharma fears “lack of focus” on no-deal Brexit preparations

supply. That is the view of Merck KGaA chief executive and President of European pharma's EFPIA, Stefan Oschmann, who says that the pharma industry has “been concerned by a certain ... While the situation at the EU-UK border remains unclear, two-thirds

Latest news

  • Novo uses voucher for speedy answer on oral semaglutide Novo uses voucher for speedy answer on oral semaglutide

    In the Pioneer programme, people treated with oral semaglutide achieved greater blood glucose reductions compared to Merck &Co's Januvia (sitagliptin) Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) and

  • Roche gets FDA nod for Tecentriq in small cell lung cancer Roche gets FDA nod for Tecentriq in small cell lung cancer

    without competition from other checkpoint inhibitors, particularly Merck &Co/MSD’s PD-1 inhibitor Keytruda (pembrolizumab) which is dominating the NSCLC category. ... Merck isn’t too far behind, however, as it is currently running a phase 3 trial

  • Urovant slips on phase 3 incontinence drug data Urovant slips on phase 3 incontinence drug data

    Vibegron was licensed from Merck &Co/MSD in 2017 and is billed as an improved version of Astellas’ Myrbetriq/Betmiga (mirabegron), which was the first beta3-adrenergic agonist to reach the

  • Keytruda adds another NSCLC approval in Europe Keytruda adds another NSCLC approval in Europe

    Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. ... MSD/Merck &Co are expecting a result from the FDA by 11 April.

  • CHMP recommends new Keytruda dosing schedule CHMP recommends new Keytruda dosing schedule

    Merck remains committed to improving the lives of people living with cancer, which includes the pursuit of innovative options for administering Keytruda to address the unique needs of patients and healthcare ... providers,” said Dr Scot Ebbinghaus

More from news
Approximately 352 fully matching, plus 1,249 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    However the last data read-out showed this hit its progression-free survival (PFS) endpoint but not OS – handing a clear advantage to Merck &Co. ... April. Naturally Merck &Co isn’t confining itself to dominance in lung cancer.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... Merck/MSD looks to have gained a dominant position in checkpoint

  • Is China ready for a pharmaceutical gold rush?

    Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    EvaluatePharma forecasts that Lynparza (now co-marketed with Merck &Co) will hit annual revenues of $2.2bn by 2024, with Imfinzi expected to reach $3.65bn and Tagrisso leading the way ... This gives it a unique niche in an IO lung cancer market dominated

More from intelligence
Approximately 8 fully matching, plus 125 partially matching documents found.

Latest appointments

More from appointments
Approximately 37 fully matching, plus 137 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 32 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics